public BRAFV600EKNotDetectedPapillaryThyroidResult() { YellowstonePathology.Business.Test.IndicationPapillaryThyroid indication = new IndicationPapillaryThyroid(); this.m_Indication = indication.IndicationCode; this.m_IndicationComment = indication.Description; this.m_Comment = "False negatives may occur if the sample does not contain a sufficient quantity of tumor DNA. If this test was performed on a " + "small/scant sample and subsequent surgical excision confirms the presence of papillary thyroid carcinoma, retesting on the surgical specimen is recommended."; this.m_Interpretation = "Papillary thyroid carcinoma (PTC) is one of the most common endocrine malignancies and accounts for " + "approximately 80% of all thyroid cancers. The BRAF gene, a member of the RAS-RAF-MEK-MAPK pathway that drives tumor growth and progression, has been found to play " + "a pivotal role in PTC oncogenesis. Recent studies have shown that approximately 40% of PTC’s harbor a point mutation in codon 600 of the BRAF gene, resulting in " + "the substitution of glutamic acid for valine in the encoded protein. This alteration results in constitutive activation of the BRAF protein kinase, and thus, the " + "RAS-RAF-MEK-MAPK pathway. Testing for the BRAF V600E/K mutation in thyroid samples is useful both for diagnosis and for risk stratification in order to guide " + "clinical operative decision making. Among all thyroid neoplasms, studies have shown that BRAF V600E/K mutations occur almost exclusively in PTC. This " + "characteristic is useful in the diagnosis of lesions that are suspicious for, but not diagnostic of, PTC on histology or fine needle aspirates. Furthermore, PTC’s " + "that harbor a BRAF V600E/K mutation exhibit more aggressive clinicopathologic features including extrathyroidal extension, lymph node metastasis, high-risk " + "histology, advanced disease stage, and greater risk for persistence and recurrence. Knowledge of the patient’s BRAF gene status may therefore confer important " + "prognostic information and allow for more individualized treatment of patients with PTC. A 107-base product indicative of a BRAF V600E/K mutation was NOT detected " + "by high resolution capillary electrophoresis."; this.m_References = BRAFV600EKResult.PapillaryThyroidReference; }
public BRAFV600EKNotDetectedPapillaryThyroidResult() { YellowstonePathology.Business.Test.IndicationPapillaryThyroid indication = new IndicationPapillaryThyroid(); this.m_Indication = indication.IndicationCode; this.m_IndicationComment = indication.Description; this.m_Comment = "False negatives may occur if the sample does not contain a sufficient quantity of tumor DNA. If this test was performed on a " + "small/scant sample and subsequent surgical excision confirms the presence of papillary thyroid carcinoma, retesting on the surgical specimen is recommended."; this.m_Interpretation = "Papillary thyroid carcinoma (PTC) is one of the most common endocrine malignancies and accounts for " + "approximately 80% of all thyroid cancers. The BRAF gene, a member of the RAS-RAF-MEK-MAPK pathway that drives tumor growth and progression, has been found to play " + "a pivotal role in PTC oncogenesis. Recent studies have shown that approximately 40% of PTC's harbor a point mutation in codon 600 of the BRAF gene, resulting in " + "the substitution of glutamic acid for valine in the encoded protein. This alteration results in constitutive activation of the BRAF protein kinase, and thus, the " + "RAS-RAF-MEK-MAPK pathway. Testing for the BRAF V600E/K mutation in thyroid samples is useful both for diagnosis and for risk stratification in order to guide " + "clinical operative decision making. Among all thyroid neoplasms, studies have shown that BRAF V600E/K mutations occur almost exclusively in PTC. This " + "characteristic is useful in the diagnosis of lesions that are suspicious for, but not diagnostic of, PTC on histology or fine needle aspirates. Furthermore, PTC's " + "that harbor a BRAF V600E/K mutation exhibit more aggressive clinicopathologic features including extrathyroidal extension, lymph node metastasis, high-risk " + "histology, advanced disease stage, and greater risk for persistence and recurrence. Knowledge of the patient's BRAF gene status may therefore confer important " + "prognostic information and allow for more individualized treatment of patients with PTC. A 107-base product indicative of a BRAF V600E/K mutation was NOT detected " + "by high resolution capillary electrophoresis."; this.m_References = BRAFV600EKResult.PapillaryThyroidReference; }
public BRAFV600EKDetectedPapillaryThyroidResult() { YellowstonePathology.Business.Test.IndicationPapillaryThyroid indication = new IndicationPapillaryThyroid(); this.m_Indication = indication.IndicationCode; this.m_IndicationComment = indication.Description; this.m_Comment = "This result indicates that the patient has a papillary thyroid carcinoma that may exhibit a more " + "aggressive clinical behavior."; this.m_Interpretation = "Papillary thyroid carcinoma (PTC) is one of the most common endocrine malignancies and " + "accounts for approximately 80% of all thyroid cancers. The BRAF gene, a member of the RAS-RAF-MEK-MAPK pathway that drives tumor growth and progression, " + "has been found to play a pivotal role in PTC oncogenesis. Recent studies have shown that approximately 40% of PTC’s harbor a point mutation in codon 600 " + "of the BRAF gene, resulting in the substitution of glutamic acid for valine in the encoded protein. This alteration results in constitutive activation of " + "the BRAF protein kinase, and thus, the RAS-RAF-MEK-MAPK pathway. Testing for the BRAF V600E/K mutation in thyroid samples is useful both for diagnosis and " + "for risk stratification in order to guide clinical operative decision making. Among all thyroid neoplasms, studies have shown that BRAF V600E/K mutations " + "occur almost exclusively in PTC. This characteristic is useful in the diagnosis of lesions that are suspicious for, but not diagnostic of, PTC on histology " + "or fine needle aspirates. Furthermore, PTC’s that harbor a BRAF V600E/K mutation exhibit more aggressive clinicopathologic features including " + "extrathyroidal extension, lymph node metastasis, high-risk histology, advanced disease stage, and greater risk for persistence and recurrence. Knowledge of " + "the patient’s BRAF gene status may therefore confer important prognostic information and allow for more individualized treatment of patients with PTC. High " + "resolution capillary electrophoresis detected a 107-base product indicative of a BRAFV600E/K mutation, thus indicating that the patient has a PTC that may " + "exhibit a more aggressive clinical behavior."; this.m_References = BRAFV600EKResult.PapillaryThyroidReference; }
public BRAFV600EKDetectedPapillaryThyroidResult() { YellowstonePathology.Business.Test.IndicationPapillaryThyroid indication = new IndicationPapillaryThyroid(); this.m_Indication = indication.IndicationCode; this.m_IndicationComment = indication.Description; this.m_Comment = "This result indicates that the patient has a papillary thyroid carcinoma that may exhibit a more " + "aggressive clinical behavior."; this.m_Interpretation = "Papillary thyroid carcinoma (PTC) is one of the most common endocrine malignancies and " + "accounts for approximately 80% of all thyroid cancers. The BRAF gene, a member of the RAS-RAF-MEK-MAPK pathway that drives tumor growth and progression, " + "has been found to play a pivotal role in PTC oncogenesis. Recent studies have shown that approximately 40% of PTC's harbor a point mutation in codon 600 " + "of the BRAF gene, resulting in the substitution of glutamic acid for valine in the encoded protein. This alteration results in constitutive activation of " + "the BRAF protein kinase, and thus, the RAS-RAF-MEK-MAPK pathway. Testing for the BRAF V600E/K mutation in thyroid samples is useful both for diagnosis and " + "for risk stratification in order to guide clinical operative decision making. Among all thyroid neoplasms, studies have shown that BRAF V600E/K mutations " + "occur almost exclusively in PTC. This characteristic is useful in the diagnosis of lesions that are suspicious for, but not diagnostic of, PTC on histology " + "or fine needle aspirates. Furthermore, PTC's that harbor a BRAF V600E/K mutation exhibit more aggressive clinicopathologic features including " + "extrathyroidal extension, lymph node metastasis, high-risk histology, advanced disease stage, and greater risk for persistence and recurrence. Knowledge of " + "the patient's BRAF gene status may therefore confer important prognostic information and allow for more individualized treatment of patients with PTC. High " + "resolution capillary electrophoresis detected a 107-base product indicative of a BRAFV600E/K mutation, thus indicating that the patient has a PTC that may " + "exhibit a more aggressive clinical behavior."; this.m_References = BRAFV600EKResult.PapillaryThyroidReference; }